Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Melanoma 4Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Skin Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Squamous Cell 1Advanced Cancer 1

Interventions

Cisplatin 76Radiotherapy 44pembrolizumab 39Cetuximab 38Paclitaxel 34Carboplatin 33Docetaxel 30Fluorouracil 25Radiotherapy, Intensity-Modulated 22Nivolumab 18Drug Therapy 14Radiation 12Erlotinib Hydrochloride 9cemiplimab 8Magnetic Resonance Spectroscopy 8130-nm albumin-bound paclitaxel 8durvalumab 7atezolizumab 7Cyclophosphamide 7Afatinib 7Surgical Procedures, Operative 6Panitumumab 6Leucovorin 6Chemoradiotherapy 6fludarabine 5aldesleukin 5Radiosurgery 5Oxaliplatin 5Methotrexate 5Gemcitabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Squamous Cell × tilsotolimod × Clear all
NCT04196283 2023-02-27

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

AbbVie

Phase 1 Completed
30 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡